Enhancements in medical marijuana research have increased substantially since the legalization of marijuana. With states like Colorado receiving $10 million in research funding, we will continue to see an increase in the knowledge and benefits of marijuana. As restrictions on cannabis testing continue to decrease, we will finally see the true reasoning behind the Government and pharmaceutical bond.
Medical marijuana patients are currently able to purchase various strains with high-THC and high-CBD levels. CBG marijuana strains are practically unavailable on the market right now, but this won’t be true for long.
Cannabinoids all start off as CBG
Cannabigerol (CBG) is a minor cannabinoid found during the early stages of the marijuana growing cycle and extracted from budding plants during their flowering stage. This makes it difficult to obtain in large quantities. Industrial hemp was recently discovered as a producer of higher levels of CBG than most cannabis strains. After further research proved the reasoning of this to be because of a recessive gene, breeders took note. Using this information, the breeders were able to create strains with a recessive gene that increases the CBG levels.
In January 2015, researchers studying CBG in mice discovered neuroprotective effects with Huntington’s disease and have shown promising results in slowing down colon cancer. CBG marijuana strains will hopefully be used therapeutically as an antidepressant, and as a functioning painkiller. Researchers suggest that CBG marijuana strains will also be beneficial for the treatment of psoriasis, glaucoma, multiple sclerosis and skin diseases.
How CBG is effective
CBG is effective in a range of treatment and therapies, according to a report by Ethan B Russo, published in the British Journal of Pharmacology. These include:
- Producing modest antifungal effects
- Inhibiting keratinocyte proliferation — may be useful in treatment of psoriasis
- In conjunction with l-limonene (citrus terpene found in cannabis), CBG shows promising results to fight breast cancer
- Pure CBG and CBD cannabinoids can powerfully inhibit MRSA
Medical marijuana patients are seeing the benefits from legalization in certain states with the boost in medical marijuana availability. The business is booming, and different strains with different benefits are being introduced rapidly to the market.
Teams of chemists in California and Oregon have developed lab testing, which is becoming an industry trend. Lab testing allows patients to be matched with a strain based on the cannabinoids profile. A Cannabinoid profile allows the patient to see the breakdown of cannabinoids in their medicine to an exact percentage. This has lead to an increase of interest in minor cannabinoids from patients, like CBD and CBG marijuana strains.
CBG coming soon
You won’t find many CBG marijuana strains currently on the market, but thanks to breeders like those at TGA genetics Subcool Seeds, the breed Mikey Kush exists. Mikey Kush strain is a Sativa-dominant strain testing with high levels of CBG and THC levels of 28.6%. CBG marijuana strains are becoming more available in Europe, and will most likely start to be seen on the shelves in North American soon. Research will surely continue, and as public interest increases, growers will be encouraged to produce high-CBG strains themselves.
With the advancement in CBG marijuana strains, it will permit growers to create CBD-CBG hybrid strains. This will introduce a whole new possibility into the future of marijuana strains. The future of medical marijuana seems positive, and both researchers and growers sound particularly optimistic about the CBG marijuana strain.
According to an article on CDXLife:
Whether incorporated in your therapy via medical marijuana or used in oil, CBG offers huge benefit to a patient who is fighting a wide range of illnesses.
Have you tried any strains with high-CBG levels? If so, be sure to let us know on social mediaSHARE